Elevated marker of IgE-mediated mast cell activation predicts omalizumab response in chronic spontaneous urticaria Written By Medha Baranwal19 Sept 2023 10:15 AM ISTOmalizumab is an anti-IgE monoclonal antibody that is suggested to be an effective treatment in chronic spontaneous urticaria.
Remibrutinib could be new effective and fast-acting oral treatment option for chronic spontaneous urticaria: Phase 3 trials Written By Dr. Kamal Kant Kohli12 Aug 2023 11:15 AM ISTSwitzerland: The phase 3 trials REMIX-1 and REMIX-2 have yielded positive top-line results, as announced by Novartis. Trials assessed remibrutinib 25...
Dupilumab improves urticaria activity and QoL in patients with chronic spontaneous urticaria Written By Medha Baranwal13 March 2023 8:00 PM ISTUSA: A recent study has found that patients with chronic spontaneous urticaria treated with dupilumab experienced a significant improvement in quality...
Sanofi Dupixent application for treatment of chronic spontaneous urticaria in adults, adolescents accepted for USFDA review Ruchika Sharma7 March 2023 3:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Sanofi, Regeneron Pharma announce positive Phase 3 data for Dupixent in adults with uncontrolled prurigo nodularis Ruchika Sharma10 Sept 2022 12:56 PM ISTPeople with prurigo nodularis experience intense, persistent itch, with thick skin lesions (called nodules) that can cover most of the body.
Dupilumab notably reduces hives and hitch in patients with chronic spontaneous urticaria: Study Written By Medha Baranwal5 May 2022 10:15 AM ISTUSA: Results from a phase 3 trial revealed that dupilumab is well-tolerated and causes significant improvement in patients with H1...
Ligelizumab improves sleep interference in chronic spontaneous urticaria patients Written By Medical Dialogues Editorial Team22 March 2022 9:00 AM ISTGermany: Ligelizumab demonstrated effective and persistent responses in managing sleep interference in chronic spontaneous urticaria (CSU) patients,...
Setback: Sanofi to halt Dupixent Phase 3 trial MD Bureau21 Feb 2022 4:50 PM ISTParis: Sanofi has recently announced that the Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous...
Ligelizumab fails to show superiority to omalizumab in chronic spontaneous urticaria: Clinical trials Written By Hina Zahid25 Dec 2021 9:00 AM ISTLigelizumab, an investigational treatment for chronic spontaneous urticaria (CSU), failed to show superiority to omalizumab in two identical phase 3...
Ligelizumab and omalizumab effective for treating chronic spontaneous urticaria: JAMA Written By MD Editorial Team28 Sept 2021 6:45 PM ISTThailand: Biologic agents ligelizumab, 72 or 240 mg, and omalizumab, 300 or 600 mg can be recommended as effective treatments for chronic spontaneous...
Dupilumab significantly improves itch and hives in chronic spontaneous urticaria patients: Study Written By Hina Zahid5 Aug 2021 9:00 AM ISTUSA: Adding Dupixent (dupilumab) to standard-of-care antihistamines significantly reduced itch and hives in patients with moderate-to-severe chronic...
Ligelizumab more effective than Omalizumab in chronic spontaneous urticaria: Study Written By Medha Baranwal6 May 2021 6:00 PM ISTUSA: Ligelizumab is more effective in reducing chronic spontaneous urticaria (CSU) severity compared with omalizumab, according to findings from a...
